Last updated: September 20, 2026
SUPREP Bowel Prep Kit is an oral bowel-cleansing product containing sodium sulfate, potassium sulfate, and magnesium sulfate. Its commercial differentiation depends less on the active salts than on excipient-controlled taste, stability, dilution performance, packaging, and patient adherence. The main opportunities are improved palatability, lower-volume administration, ready-to-use delivery, private-label supply, and differentiated formulations that preserve the product's sulfate-based cleansing profile.
What is the SUPREP Bowel Prep Kit formulation?
SUPREP is supplied as two 6-ounce bottles of an oral solution concentrate. Each bottle contains:
| Component |
Amount per 6-ounce bottle |
Functional role |
| Sodium sulfate |
17.5 g |
Osmotic cleansing agent |
| Potassium sulfate |
3.13 g |
Osmotic cleansing agent and potassium source |
| Magnesium sulfate |
1.6 g |
Osmotic cleansing agent |
| Citric acid |
Not publicly quantified in the prescribing information |
Acidulant and flavor-balancing agent |
| Flavoring |
Not publicly quantified |
Taste masking |
| Sodium benzoate |
Not publicly quantified |
Preservative |
| Purified water |
q.s. |
Liquid vehicle |
The concentrate is diluted with water before administration. The labeled regimen requires the patient to consume the diluted preparation followed by additional water, with a second dose later in the regimen. The formulation is therefore a combination of active osmotic salts, acidulant, flavor system, preservative, and packaging components rather than a conventional ready-to-drink liquid.
The FDA-approved product is marketed under the SUPREP Bowel Prep Kit name by Braintree Laboratories, a subsidiary of Sebela Pharmaceuticals. The original U.S. approval was NDA 022372 in 2010.[1]
Why do excipients matter commercially for SUPREP?
Excipient performance directly affects adherence, product differentiation, and substitutability. Sulfate-based bowel preparations have a strong salty, bitter, and mineral taste. The excipient system must reduce that sensory burden without compromising chemical stability or increasing microbial risk.
The highest-value formulation objectives are:
- Reduce sulfurous, bitter, and saline taste.
- Maintain clarity and uniformity after dilution.
- Prevent precipitation or crystallization during storage and use.
- Preserve stability across the labeled temperature range.
- Limit preservative-related irritation.
- Improve patient acceptance without materially increasing dose volume.
- Support scalable filling into small, high-barrier bottles.
A formulation that changes only flavor may have limited regulatory or patent strength. A commercially stronger product would combine taste masking with a measurable technical benefit, such as improved stability, reduced dosing volume, simplified dilution, or compatibility with an alternative container-closure system.
What excipients are most important in a SUPREP reformulation?
Flavoring and taste-masking systems
Flavoring is the most obvious commercial target. Citrus profiles are logical because citric acid already contributes acidity and can reduce the perception of saltiness. Potential systems include lemon, lime, orange, grapefruit, and blended citrus profiles.
The main technical constraint is that a flavor must remain acceptable at high ionic strength. Many conventional flavor systems lose impact or develop off-notes in concentrated sulfate solutions. The commercial opportunity is a flavor system specifically engineered for high-osmolality, high-salt oral liquids.
A differentiated product could use:
- Encapsulated flavor oils;
- Water-soluble citrus flavors;
- Sweetener systems with low gastrointestinal activity;
- Cooling agents used at low concentrations;
- Sequential flavor-release systems;
- Flavor systems compatible with dilution in cold water.
Sweeteners require careful selection. Polyols can worsen gastrointestinal symptoms, while high-intensity sweeteners may introduce metallic or bitter aftertastes. Sucralose, acesulfame potassium, saccharin, and steviol glycosides each create different regulatory and sensory profiles.
Citric acid and pH control
Citric acid supports flavor balance and pH control. Changes in acid concentration can affect:
- Perceived saltiness;
- Preservative effectiveness;
- Chemical stability;
- Container compatibility;
- Patient tolerance;
- Potential precipitation after dilution.
A reformulator should treat pH as a critical quality attribute rather than merely a flavor parameter. Any pH adjustment must be evaluated against the sulfate salts, preservative system, flavor components, and closure materials.
Sodium benzoate and preservation
Sodium benzoate provides antimicrobial protection in the liquid concentrate. Its effectiveness depends on pH, water activity, manufacturing controls, and container integrity.
A commercial alternative could use a different preservative system, a lower preservative concentration, or a preservative-free package. Preservative-free SUPREP-like products would require strong container-closure and aseptic or controlled manufacturing strategies. That approach could create differentiation but would raise development and validation costs.
A preservative substitution can also create an ANDA or 505(b)(2) regulatory issue if the change affects formulation composition, stability, microbiological attributes, or labeling.
Water quality and container compatibility
Purified water is a core formulation input. Water quality affects ionic balance, microbial control, and batch consistency. Because the product is a concentrated electrolyte solution, minor changes in water composition can influence stability and sensory properties.
The bottle, cap, liner, label adhesive, and secondary packaging are also part of the commercial formulation strategy. Extractables and leachables, flavor sorption, light exposure, and closure integrity are relevant risks. Citrus flavor components can interact with certain polymers and elastomers, making packaging screening necessary before scale-up.
What formulations are protected by SUPREP-related intellectual property?
The strongest protectable subject matter is more likely to arise from formulation performance and delivery design than from the individual sulfate salts. Sodium sulfate, potassium sulfate, magnesium sulfate, citric acid, flavoring, sodium benzoate, and purified water are established pharmaceutical ingredients.
Potential intellectual-property positions include:
| IP category |
Potential claim focus |
Commercial value |
| Composition |
Defined sulfate ratio, pH, osmolality, or excipient range |
Moderate if linked to unexpected performance |
| Taste masking |
Specific flavor and sweetener combination |
Moderate, but design-around risk is high |
| Stability |
Shelf-life performance in concentrate form |
Moderate to strong if supported by comparative data |
| Packaging |
Bottle, closure, liner, or light-barrier configuration |
Moderate |
| Dosing regimen |
Split-dose administration and hydration instructions |
Generally dependent on method-of-use law and prior art |
| Manufacturing |
Mixing order, temperature, filtration, or filling process |
Stronger where process controls affect quality |
| Patient-use system |
Pre-measured dilution cup or integrated water-delivery system |
Commercially useful, but often easy to design around |
The patent estate should be evaluated against the current FDA Orange Book and USPTO records before investment or licensing decisions. Product-level protection is weaker where claims cover only well-known salts in conventional oral-liquid formats. Patent strength improves when a formulation claim connects a specific excipient range to a demonstrated reduction in bitterness, improved stability, reduced precipitation, or better adherence.
When does SUPREP lose exclusivity?
SUPREP's five-year new chemical entity exclusivity is no longer active. The product was approved in 2010, and its current competitive position depends primarily on patents, regulatory exclusivity, trademarks, manufacturing know-how, and commercial relationships.
The FDA product label identifies the approved formulation and dosing regimen, while the Orange Book determines whether listed patents remain relevant to ANDA certification and Paragraph IV litigation.[1,2] The practical barrier to generic entry is therefore not current NCE exclusivity. It is the combination of formulation equivalence, manufacturing consistency, labeling, litigation risk, and market access.
A generic applicant can pursue an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence or satisfy the applicable FDA requirements for this type of locally acting bowel-cleansing product. A reformulated competitor may instead consider a 505(b)(2) pathway where it relies partly on FDA findings for the reference product while pursuing a differentiated formulation, delivery system, or dosing regimen.[3]
What is the Orange Book status of SUPREP?
SUPREP is listed in FDA product databases under NDA 022372. The Orange Book remains the controlling source for current patent listings, therapeutic-equivalence codes, and approved multisource products.[2]
For commercial diligence, the relevant questions are:
- Whether current patents remain listed against NDA 022372;
- Whether any listed patents cover formulation, method of use, or both;
- Whether a generic applicant has submitted a Paragraph IV certification;
- Whether FDA approval is stayed under Hatch-Waxman;
- Whether approved generic products have an AB rating;
- Whether authorized-generic or licensed supply arrangements exist.
Patent status can change through delisting, expiration, terminal disclaimers, litigation settlements, or FDA approval of competing products. A market entrant should not treat an old Orange Book patent listing as an absolute barrier to launch.
Which companies are challenging or competing with SUPREP?
The competitive set includes several product classes:
| Product class |
Examples |
Competitive basis |
| Sulfate oral solution |
SUPREP and generic equivalents |
Lower formulation complexity and direct substitution |
| Sulfate tablets |
SUTAB |
Lower liquid burden, higher tablet count |
| PEG-electrolyte solutions |
GoLYTELY, MiraLAX-based regimens |
Familiarity and broad clinical use |
| Sodium picosulfate products |
CLENPIQ and related products |
Different active mechanism and dosing profile |
| Magnesium citrate regimens |
Various prescription and nonprescription products |
Cost and availability |
SUTAB competes directly for patients who dislike liquid preparations but accept a larger tablet burden. PEG products compete on clinical familiarity and physician preference. Generic sulfate solutions create the greatest direct price pressure because they can offer the same active ingredients and a similar dosing architecture.
What commercial opportunities exist in SUPREP excipient strategy?
Premium taste-masked sulfate solution
A premium product could retain the sulfate actives while using a stronger flavor system, lower bitterness, and better post-dilution acceptability. The commercial value would depend on demonstrated adherence or patient-preference data rather than taste-panel claims alone.
Lower-volume concentrate
The active sulfate load limits how far volume can be reduced. Still, improved concentration, more efficient dilution instructions, or a smaller total hydration burden could create a meaningful positioning advantage. Any reduction in required water must be evaluated against dehydration, renal, and electrolyte safety considerations.
Ready-to-use or single-dose packaging
A ready-to-use presentation could reduce preparation errors and improve convenience. The tradeoff is higher shipping weight, larger packaging, preservative requirements, and potentially shorter stability. A single-dose bottle or pre-measured dilution system could support hospital, ambulatory surgery, and direct-to-consumer channels.
Private-label and contract manufacturing
The formulation uses widely available active ingredients and standard oral-liquid manufacturing processes. A qualified manufacturer could supply regional health systems, pharmacy chains, telehealth companies, or procedure-center networks.
The principal barriers are:
- Consistent sourcing of pharmaceutical-grade sulfate salts;
- Control of high-salt liquid filling;
- Flavor and preservative uniformity;
- Stability in the final container;
- FDA-compliant labeling;
- Reliable supply of bottles and closures.
Combination with digital patient support
A dosing reminder, hydration tracker, or procedure-preparation platform could improve completion rates. The software would not create formulation exclusivity, but it could improve channel value for gastroenterology practices, ambulatory surgery centers, and telehealth providers.
What generic launch risks exist for SUPREP?
Generic entry risks are primarily commercial and regulatory:
- Price erosion from AB-rated products.
- Loss of formulary preference.
- Pharmacy substitution where state law permits.
- Reduced prescriber control over flavor and packaging.
- Lower margins from ingredient commoditization.
- Litigation delay if Orange Book patents remain enforceable.
- Supply disruption caused by high-volume procedure demand.
- Patient dissatisfaction if a generic flavor system performs poorly.
The reference product can defend share through flavor consistency, physician familiarity, supply reliability, packaging, and institutional contracts. These protections are weaker than patent exclusivity but can delay rapid conversion.
How strong is the SUPREP patent estate?
The estate is strongest where it protects a defined formulation or manufacturing process with measurable technical performance. It is weaker where claims cover the general use of sulfate salts for bowel cleansing or routine flavor and preservative combinations.
A practical strength assessment should score:
| Factor |
Assessment |
| Active-ingredient novelty |
Low |
| Excipient novelty |
Low to moderate |
| Formulation-performance data |
Determines claim value |
| Manufacturing know-how |
Moderate |
| Packaging differentiation |
Moderate |
| Method-of-use protection |
Dependent on claim scope and prior art |
| Generic substitution risk |
High after patent and exclusivity barriers fall |
| Biosimilar risk |
Not applicable |
Is there biosimilar risk for SUPREP?
No. SUPREP is a small-molecule oral liquid, not a biologic. Biosimilar pathways do not apply. Competitive entry occurs through generic, authorized-generic, 505(b)(2), or reformulated prescription-product pathways.
Key Takeaways
- SUPREP's core commercial asset is the sulfate oral-solution platform, not a novel excipient.
- Flavor masking, pH control, preservative selection, and packaging are the main formulation levers.
- A differentiated product needs measurable performance advantages, not a cosmetic flavor change.
- NCE exclusivity is no longer a barrier; Orange Book patents and regulatory pathway selection determine launch risk.
- Generic sulfate solutions create direct price pressure.
- The strongest opportunities are premium taste masking, lower-volume delivery, ready-to-use packaging, private-label supply, and patient-adherence systems.
- Biosimilar competition does not apply.
- Manufacturing quality, supply reliability, and institutional contracting may provide greater practical protection than weak formulation patents.
FAQs
Can SUPREP be reformulated without changing the active ingredients?
Yes. A reformulation can modify flavor, sweetener, preservative, pH, packaging, or delivery format, but the regulatory pathway depends on the extent of the change and the sponsor's reliance on the reference product.
Is a flavor improvement alone enough to support a new SUPREP patent?
Usually not. A flavor claim is stronger when tied to a defined composition and demonstrated technical result, such as reduced bitterness, improved stability, or superior patient acceptance.
What is the best excipient opportunity for a generic SUPREP product?
Taste masking is the most direct opportunity. Packaging and dosing convenience can add commercial value, but the product must remain pharmaceutically equivalent and operationally reliable.
Can a SUPREP competitor use a preservative-free formulation?
Potentially, but the product would need validated microbial control, container-closure integrity, stability, and manufacturing controls. The cost and regulatory burden may outweigh the commercial benefit.
Is SUTAB a direct generic substitute for SUPREP?
No. SUTAB is a tablet-based bowel-preparation product with a different dosage form and administration burden. It competes commercially but is not a direct liquid-solution equivalent.
References
- U.S. Food and Drug Administration. (2010). SUPREP Bowel Prep Kit prescribing information, NDA 022372. FDA.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
- U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA.
